Anti-Fungal Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Antifungal Drugs Treatment Market Report is Segmented by Drug Type (Echinocandins, Azoles, Polyenes, Allylamines, and Other Drug Types), Indication (Aspergillosis, Dermatophytosis, Candidiasis, and Other Indications), Dosage Form (Powders, Ointments, Tablets, and Other Dosage Forms), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (USD) for the Above Segments.

Anti-Fungal Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Antifungal Drugs Market Size

Antifungal Drugs Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 17.26 Billion
Market Size (2030) USD 20.90 Billion
CAGR (2025 - 2030) 3.90 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Low

Major Players

Antifungal Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Antifungal Drugs Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Antifungal Drugs Market Analysis

The Antifungal Drugs Market size is estimated at USD 17.26 billion in 2025, and is expected to reach USD 20.90 billion by 2030, at a CAGR of 3.9% during the forecast period (2025-2030).

The major factors contributing to the growth of the anti-fungal drugs market include increased awareness of many fungal infections, rising numbers of over-the-counter (OTC) anti-fungal drugs, and increased use of antimicrobial drugs in developing countries. The growing popularity of OTC drugs such as clotrimazole, econazole, ketoconazole, miconazole, and amorolfine has resulted in many patients using OTC drugs.

An increase in onychomycosis cases, a fungal infection of the fingers and toes, is also expected to contribute to the market’s growth. For instance, according to the data updated by the CDC in September 2022, onychomycosis affected up to 14% of the general population in the world, and fungal toenail infections became more common than fungal fingernail infections.

Additionally, excessive glucose can lead to high cellular damage, resulting in several infectious and non-infectious skin disorders. Therefore, diabetes patients are more susceptible to various fungal infections, and onychomycosis is one of the major infections among the target population. For instance, according to an article published in the Journal of Fungi in August 2022, when a group of people was studied for skin and nail disorders in diabetic patients, onychomycoses were found common in critically ill diabetic patients.

Furthermore, the same study stated that dermatophytes were found to be the commonest cultural isolates (50%), followed by yeasts and molds in 30.8% and 19.2%, respectively, of the diabetes patients. Hence, the high burden of diseases among the target population is expected to increase the demand for antifungals and contribute to the overall growth of the market studied over the forecast period.

Moreover, the increasing focus of companies on adopting key strategic activities such as product launches, mergers and acquisitions, collaborations, and partnerships is further expected to boost the availability of anti-fungal drugs in the market over the forecast period. For instance, in June 2022, Apex Labs introduced the advanced Supra Bioavailable Itraconazole 65 and 130 mg capsules, a potent therapeutic option for effectively controlling fungal infections. Supra Bioavailable Itraconazole capsules deliver a higher percentage (90%) of active medicine to the biological system at a lesser dose. This advanced preparation also ensures lesser inter-individual variability, which may translate into enhanced efficacy in the management of fungal infections, according to a statement from the company.

Thus, the growing incidence of fungal infection and strategic activities adopted by market players is expected to contribute to market growth over the forecast period. However, increasing resistance to anti-fungal drugs and the side effects of these drugs are anticipated to hinder their adoption and demand, thereby restraining the market's growth.

Antifungal Drugs Industry Overview

The analyzed market is fragmented, primarily due to the presence of a limited number of smaller players and several major industry players. The market participants are actively engaged in launching new products and obtaining approvals for them, which is anticipated further to intensify the competitive environment within the studied market. Among the significant market players are Abbott Laboratories, Bayer AG, Astellas Pharma Inc., Glenmark Pharmaceuticals Limited, GSK PLC, Merck & Co. Inc., Novartis AG, and Pfizer Inc.

Antifungal Drugs Market Leaders

  1. Abbott Laboratories

  2. Bayer AG

  3. Merck & Co., Inc.

  4. Glenmark Pharmaceuticals Limited

  5. GSK plc

  6. *Disclaimer: Major Players sorted in no particular order
Antifungal Drugs Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Antifungal Drugs Market News

  • June 2024: Elion Therapeutics, a biotech company headquartered in New York, secured USD 81 million in funding through its Series B round. The funding is specifically earmarked for advancing its early-stage polyene anti-fungal therapy, SF001.
  • January 2024: Fresenius Kabi introduced Posaconazole Injection, a generic substitute for Noxafil, for use in treating or preventing serious fungal infections in adults and children who have an increased chance of getting these infections due to a weakened immune system.

Antifungal Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumption and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Awareness about Fungal Infections
    • 4.2.2 Increasing Number of Antifungal Drugs as Over-the-counter (OTC)
    • 4.2.3 Rising Consumption of Antifungal Drugs in Developing Regions
  • 4.3 Market Restraints
    • 4.3.1 Increasing Resistance to Antifungal Drugs
    • 4.3.2 Side Effects of Antifungal Drugs and Product Recalls
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Drug Type
    • 5.1.1 Echinocandins
    • 5.1.2 Azoles
    • 5.1.3 Polyenes
    • 5.1.4 Allylamines
    • 5.1.5 Other Drug Types
  • 5.2 By Indication
    • 5.2.1 Aspergillosis
    • 5.2.2 Dermatophytosis
    • 5.2.3 Candidiasis
    • 5.2.4 Other Indications
  • 5.3 By Dosage Form
    • 5.3.1 Powders
    • 5.3.2 Ointments
    • 5.3.3 Tablets
    • 5.3.4 Other Dosage Forms
  • 5.4 By Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Astellas Pharma Inc.
    • 6.1.3 Bayer AG
    • 6.1.4 GSK plc
    • 6.1.5 Glenmark Pharmaceuticals Limited
    • 6.1.6 Arcadia Consumer Healthcare
    • 6.1.7 Merck & Co. Inc.
    • 6.1.8 Novartis AG
    • 6.1.9 Pfizer Inc.
    • 6.1.10 SCYNEXIS Inc.
    • 6.1.11 Mycovia Pharmaceuticals Inc.
    • 6.1.12 Apex Laboratories Pvt. Ltd
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Antifungal Drugs Industry Segmentation

As per the scope of this report, anti-fungal drugs are used/prescribed for the treatment of diseases caused by fungi. The anti-fungal drugs market is segmented by drug type, indication, dosage form, and geography. By drug type, the market is segmented as echinocandins, azoles, polyenes, allylamines, and other drug types. By indication, the market is segmented as aspergillosis, dermatophytosis, candidiasis, and other indications. By dosage form, the market is segmented as powder, ointments, tablets, and other dosage forms. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (USD) for the above segments.

By Drug Type Echinocandins
Azoles
Polyenes
Allylamines
Other Drug Types
By Indication Aspergillosis
Dermatophytosis
Candidiasis
Other Indications
By Dosage Form Powders
Ointments
Tablets
Other Dosage Forms
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Antifungal Drugs Market Research FAQs

How big is the Antifungal Drugs Market?

The Antifungal Drugs Market size is expected to reach USD 17.26 billion in 2025 and grow at a CAGR of 3.9% to reach USD 20.90 billion by 2030.

What is the current Antifungal Drugs Market size?

In 2025, the Antifungal Drugs Market size is expected to reach USD 17.26 billion.

Who are the key players in Antifungal Drugs Market?

Abbott Laboratories, Bayer AG, Merck & Co., Inc., Glenmark Pharmaceuticals Limited and GSK plc are the major companies operating in the Antifungal Drugs Market.

Which is the fastest growing region in Antifungal Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Antifungal Drugs Market?

In 2025, the North America accounts for the largest market share in Antifungal Drugs Market.

What years does this Antifungal Drugs Market cover, and what was the market size in 2024?

In 2024, the Antifungal Drugs Market size was estimated at USD 16.59 billion. The report covers the Antifungal Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Antifungal Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Antifungal Drugs Industry Report

Statistics for the 2025 Antifungal Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Antifungal Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.